WO1999006550A3 - 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE - Google Patents

5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE Download PDF

Info

Publication number
WO1999006550A3
WO1999006550A3 PCT/IB1998/001232 IB9801232W WO9906550A3 WO 1999006550 A3 WO1999006550 A3 WO 1999006550A3 IB 9801232 W IB9801232 W IB 9801232W WO 9906550 A3 WO9906550 A3 WO 9906550A3
Authority
WO
WIPO (PCT)
Prior art keywords
ests
secreted proteins
prostate
proteins expressed
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB1998/001232
Other languages
French (fr)
Other versions
WO1999006550A2 (en
WO1999006550B1 (en
Inventor
Milne Edwards Jean-Bapti Dumas
Aymeric Duclert
Bruno Lacroix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Biodevelopment SAS
Original Assignee
Genset SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset SA filed Critical Genset SA
Priority to JP2000505291A priority Critical patent/JP2001512013A/en
Priority to EP98936590A priority patent/EP1000148A2/en
Priority to AU85551/98A priority patent/AU8555198A/en
Priority to CA002296287A priority patent/CA2296287A1/en
Publication of WO1999006550A2 publication Critical patent/WO1999006550A2/en
Publication of WO1999006550A3 publication Critical patent/WO1999006550A3/en
Publication of WO1999006550B1 publication Critical patent/WO1999006550B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The sequences of 5' ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5' ESTs may be to obtain cDNAs and genomic DNAs corresponding to the 5' ESTs. The 5' ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be obtained using the 5' ESTs. The 5' ESTs may also be used to design expression vectors and secretion vectors.
PCT/IB1998/001232 1997-08-01 1998-07-31 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE Ceased WO1999006550A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000505291A JP2001512013A (en) 1997-08-01 1998-07-31 5'EST of secreted protein expressed in prostate
EP98936590A EP1000148A2 (en) 1997-08-01 1998-07-31 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE
AU85551/98A AU8555198A (en) 1997-08-01 1998-07-31 5' ests for secreted proteins expressed in prostate
CA002296287A CA2296287A1 (en) 1997-08-01 1998-07-31 5' ests for secreted proteins expressed in prostate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90514497A 1997-08-01 1997-08-01
US08/905,144 1997-08-01

Publications (3)

Publication Number Publication Date
WO1999006550A2 WO1999006550A2 (en) 1999-02-11
WO1999006550A3 true WO1999006550A3 (en) 1999-04-29
WO1999006550B1 WO1999006550B1 (en) 1999-06-03

Family

ID=25420349

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1998/001232 Ceased WO1999006550A2 (en) 1997-08-01 1998-07-31 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE

Country Status (5)

Country Link
EP (1) EP1000148A2 (en)
JP (1) JP2001512013A (en)
AU (1) AU8555198A (en)
CA (1) CA2296287A1 (en)
WO (1) WO1999006550A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7569356B2 (en) 1999-10-28 2009-08-04 Agensys, Inc. Diagnosis and therapy of cancer using SGP28-related molecules
US9617346B2 (en) 2004-04-22 2017-04-11 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US11180571B2 (en) 2017-04-03 2021-11-23 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656480B2 (en) * 1996-01-11 2003-12-02 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
WO2000075327A1 (en) * 1999-06-02 2000-12-14 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6613872B1 (en) 1997-02-25 2003-09-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
HUP0002095A3 (en) 1997-02-25 2002-02-28 Corixa Corp Seattle Compounds for immunotherapy of prostate cancer and methods for their use
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6956108B2 (en) 1997-06-16 2005-10-18 Genentech, Inc. PRO1184 antibodies
US6548633B1 (en) 1998-12-22 2003-04-15 Genset, S.A. Complementary DNA's encoding proteins with signal peptides
AU2003262114B8 (en) * 1998-02-09 2006-08-03 Serono Genetics Institute S.A. cDNAs encoding secreted proteins
JP2002502605A (en) * 1998-02-09 2002-01-29 ジェンセット CDNA encoding secreted protein
US7049063B2 (en) 1998-03-18 2006-05-23 Corixa Corporation Methods for diagnosis of lung cancer
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6737514B1 (en) 1998-12-22 2004-05-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6660838B1 (en) 1998-03-18 2003-12-09 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US6365369B1 (en) 1998-04-01 2002-04-02 Human Genome Sciences, Inc. Prostate specific secreted protein
GB9807723D0 (en) * 1998-04-08 1998-06-10 Smithkline Beecham Plc Novel compounds
DE19818620A1 (en) * 1998-04-21 1999-10-28 Metagen Gesellschaft Fuer Genomforschung Mbh New polypeptides and their nucleic acids, useful for treatment of bladder tumor and identification of therapeutic agents
US7105639B2 (en) 1998-05-15 2006-09-12 Genentech, Inc. Anti-PRO 4405 antibodies
AU3952699A (en) * 1998-05-19 1999-12-06 Compugen Ltd. Metabotropic glutamate receptor-like protein and encoding cdna
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
AU757698C (en) 1998-06-01 2004-04-08 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
AU761340B2 (en) * 1998-06-02 2003-06-05 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7264801B2 (en) 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
AU5447899A (en) * 1998-09-03 2000-03-27 Takeda Chemical Industries Ltd. Novel protein and process for producing the same
CA2342833A1 (en) * 1998-09-17 2000-03-23 Incyte Pharmaceuticals, Inc. Human gpcr proteins
ES2289630T3 (en) * 1999-03-08 2008-02-01 Genentech, Inc. COMPOSITIONS AND PROCEDURES FOR TUMORS DIAGNOSIS.
ATE417063T1 (en) 1999-03-23 2008-12-15 Genentech Inc SECRETED TRANSMEMBRANE PROTEINS AND NUCLEIC ACIDS CODING THEREFOR
US7244827B2 (en) 2000-04-12 2007-07-17 Agensys, Inc. Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
IL145775A0 (en) * 1999-04-12 2002-07-25 Agensys Inc 13 transmembrane protein expressed in prostate cancer
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
EP1792989A1 (en) * 1999-04-12 2007-06-06 Agensys, Inc. 13 Transmembrane protein expressed in prostate cancer
AU3774300A (en) * 1999-06-02 2000-12-18 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU5458300A (en) * 1999-06-07 2000-12-28 Human Genome Sciences, Inc. 26 human secreted proteins
US7033780B1 (en) 1999-06-14 2006-04-25 Millennium Pharmaceuticals, Inc. Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
US20030022279A1 (en) 1999-06-14 2003-01-30 Fraser Christopher C. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
EP1194545A2 (en) * 1999-06-23 2002-04-10 Curagen Corporation Secreted polypeptides and corresponding polynucleotides
CA2381327A1 (en) * 1999-07-16 2001-01-25 Steven M. Ruben Human tumor necrosis factor receptors tr13 and tr14
US6951738B2 (en) 1999-07-16 2005-10-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptors TR13 and TR14
WO2001010902A2 (en) * 1999-08-11 2001-02-15 Curagen Corporation Nucleoc acids and secreted polypeptides encoded thereby
CA2384749A1 (en) * 1999-09-13 2001-03-22 Curagen Corporation Novel human proteins, polynucleotides encoding them and methods of using the same
DK1220913T3 (en) * 1999-10-05 2009-03-16 Agensys Inc G protein coupled receptor up-regulated in prostate cancer and its uses
US7208280B2 (en) 1999-10-05 2007-04-24 Agensys, Inc. Nucleic acid and corresponding protein entitled 101P3A41 useful in treatment and detection of cancer
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
EP1598671A1 (en) * 1999-10-28 2005-11-23 Agensys, Inc. Diagnosis and therapy of cancer using SGP28-related molecules
FR2800388A1 (en) * 1999-10-29 2001-05-04 Pf Medicament CLONING, EXPRESSION AND CHARACTERIZATION OF A GENE EXPRESSED IN TUMOR CELLS AND INVOLVED IN REGULATION OF THE IMMUNE RESPONSE
EP1230362A2 (en) * 1999-11-16 2002-08-14 ZymoGenetics, Inc. Human zven proteins
US6485938B1 (en) 1999-11-16 2002-11-26 Zymogenetics, Inc. Nucleic acid molecules that encodes human Zven1
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
US20020037513A1 (en) * 2000-03-24 2002-03-28 Rosana Kapeller-Libermann 33338, a novel human ubiquitin hydrolase-like molecule and uses thereof
KR100961345B1 (en) * 2000-06-23 2010-06-04 제넨테크, 인크. EV-VEEP nucleic acids and polypeptides and methods of use
US7045299B2 (en) 2000-07-18 2006-05-16 Takeda Pharmaceutical Company Limited Physiologically active peptide and use thereof
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002062996A1 (en) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Novel physiologically active peptide and use thereof
AUPR311601A0 (en) * 2001-02-15 2001-03-08 Adp Pharmaceutical Pty Limited Matrix gene expression in chondrogenesis
US7070584B2 (en) 2001-02-20 2006-07-04 Kci Licensing, Inc. Biocompatible wound dressing
US7927597B2 (en) 2001-04-10 2011-04-19 Agensys, Inc. Methods to inhibit cell growth
EP2280030A3 (en) 2001-04-10 2011-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
AU2002336446B2 (en) 2001-09-06 2008-03-06 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
CA2500962A1 (en) 2002-10-07 2004-04-15 Zymogenetics, Inc. Uses of human zven proteins and polynucleotides
AU2002352976B2 (en) * 2002-11-27 2007-11-08 Agensys, Inc. Nucleic acid corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
AU2004219592C1 (en) 2003-03-12 2011-02-24 Genentech, Inc. Use of Bv8 and/or EG-VEGF to promote hematopoiesis
FR2982860B1 (en) * 2011-11-18 2015-07-10 Ass Fr Contre Les Myopathies USE OF FIBROMODULIN AND LUMICAN TO INCREASE MUSCLE MASS
GB201511792D0 (en) * 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
CR20170579A (en) 2015-07-06 2018-05-25 Immatics Biotechnologies Gmbh NEW PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGIC CANCER AND OTHER CANCER.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279582A2 (en) * 1987-02-17 1988-08-24 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
EP0625572A1 (en) * 1992-09-25 1994-11-23 The Kanagawa Academy Of Science And Technology Foundation PROCESS FOR SYNTHESIZING COMPLETE-LENGTH cDNA, PROCESS FOR PRODUCING INTERMEDIATE THEREFOR, AND PROCESS FOR PRODUCING RECOMBINANT VECTOR CONTAINING COMPLETE-LENGTH cDNA
WO1996034981A2 (en) * 1995-05-02 1996-11-07 Genset Sa METHOD FOR THE SPECIFIC COUPLING OF THE CAP OF THE EXTREMITY 5' OF A FRAGMENT mRNA AND PREPARATION OF mRNA AND COMPLETE cDNA
WO1997007198A2 (en) * 1995-08-11 1997-02-27 Genetics Institute, Inc. Dna sequences and secreted proteins encoded thereby

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279582A2 (en) * 1987-02-17 1988-08-24 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
EP0625572A1 (en) * 1992-09-25 1994-11-23 The Kanagawa Academy Of Science And Technology Foundation PROCESS FOR SYNTHESIZING COMPLETE-LENGTH cDNA, PROCESS FOR PRODUCING INTERMEDIATE THEREFOR, AND PROCESS FOR PRODUCING RECOMBINANT VECTOR CONTAINING COMPLETE-LENGTH cDNA
WO1996034981A2 (en) * 1995-05-02 1996-11-07 Genset Sa METHOD FOR THE SPECIFIC COUPLING OF THE CAP OF THE EXTREMITY 5' OF A FRAGMENT mRNA AND PREPARATION OF mRNA AND COMPLETE cDNA
WO1997007198A2 (en) * 1995-08-11 1997-02-27 Genetics Institute, Inc. Dna sequences and secreted proteins encoded thereby

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ADAMS M D ET AL: "INITIAL ASSESSMENT OF HUMAN GENE DIVERSITY AND EXPRESSION PATTERNS BASED UPON 83 MILLION NUCLEOTIDES OF CDNA SEQUENCE", NATURE, vol. 377, no. SUPPL, 28 September 1995 (1995-09-28), pages 3 - 17, XP002069461 *
CARNINCI P. ET AL.: "High-efficiency full-length cDNA cloning by biotinylated CAP trapper", GENOMICS, vol. 37, no. 3, 1 November 1996 (1996-11-01), pages 327 - 336, XP002081729 *
DATABASE EMBL - EMEST16 21 December 1996 (1996-12-21), MARRA, M. ET AL.: "ms49f10.r1 Life Tech mouse embryo 13 5dpc 10666014 Mus musculus cDNA clone 614923 5'.", XP002083641 *
DATABASE EMBL - EMEST8 4 July 1997 (1997-07-04), STRAUSBERG, R.: "nh46a08.s1 NCI_CGAP_Pr5 Homo sapiens cDNA clone IMAGE:955382 similar to gb:M21895 PROSTATE SPECIFIC ANTIGEN PRECURSOR (HUMAN).", XP002083802 *
DATABASE EMBL - EMHUM2 6 February 1997 (1997-02-06), FRANCIS, F. ET AL.: "H. sapiens PEX gene", XP002083642 *
GREENWOOD M T ET AL: "Cloning of the gene encoding human somatostatin receptor 2: sequence analysis of the 5@?-flanking promoter region", GENE, vol. 159, no. 2, 4 July 1995 (1995-07-04), pages 291-292, XP004042228 *
HEIJNE VON G.: "A new method for predicting signal sequence cleavage sites", NUCLEIC ACIDS RESEARCH, vol. 14, no. 11, 1986, pages 4683 - 4690, XP002053954 *
KATO S. ET AL.: "Construction of a human full-length cDNA bank", GENE, vol. 150, 1994, pages 243 - 250, XP002081364 *
LIN Y ET AL: "INHIBITION OF NUCLEAR TRANSLOCATION OF TRANSCRIPTION FACTOR NF-KB BY A SYNTHETIC PEPTIDE CONTAINING A CELL MEMBRANE-PERMEABLE MOTIF AND NUCLEAR LOCALIZATION SEQUENCE", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 24, 16 June 1995 (1995-06-16), pages 14255 - 14258, XP002050723 *
LOCKHART D J ET AL: "EXPRESSION MONITORING BY HYBRIDIZATION TO HIGH-DENSITY OLIGONUCLEOTIDE ARRAYS", BIO/TECHNOLOGY, vol. 14, no. 13, December 1996 (1996-12-01), pages 1675 - 1680, XP002022521 *
LUNDWALL A ET AL: "MOLECULAR CLONING OF HUMAN PROSTATE SPECIFIC ANTIGEN CDNA", FEBS LETTERS, vol. 214, no. 2, April 1987 (1987-04-01), pages 317 - 322, XP000605372 *
TASHIRO K. ET AL.: "Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins", SCIENCE, vol. 261, 30 July 1993 (1993-07-30), pages 600 - 603, XP000673204 *
YOKOYAMA-KOBAYASHI M. ET AL.: "A signal sequence detection system using secreted protease activity as an indicator", GENE, vol. 163, 1995, pages 193 - 196, XP002053953 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7569356B2 (en) 1999-10-28 2009-08-04 Agensys, Inc. Diagnosis and therapy of cancer using SGP28-related molecules
US9617346B2 (en) 2004-04-22 2017-04-11 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US10597463B2 (en) 2004-04-22 2020-03-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US11401347B2 (en) 2004-04-22 2022-08-02 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US11180571B2 (en) 2017-04-03 2021-11-23 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1
US11685790B2 (en) 2017-04-03 2023-06-27 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1

Also Published As

Publication number Publication date
CA2296287A1 (en) 1999-02-11
AU8555198A (en) 1999-02-22
EP1000148A2 (en) 2000-05-17
WO1999006550A2 (en) 1999-02-11
WO1999006550B1 (en) 1999-06-03
JP2001512013A (en) 2001-08-21

Similar Documents

Publication Publication Date Title
WO1999006552A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN BRAIN
WO1999006548A3 (en) 5'ESTs FOR NON TISSUE SPECIFIC SECRETED PROTEINS
WO1999006549A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN TESTIS AND OTHER TISSUES
WO1999053051A3 (en) 5' ests and encoded human proteins
EP1033401A3 (en) Expressed sequence tags and encoded human proteins
WO1999006554A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES
WO1999006551A3 (en) 5' ESTs FOR SECRETED PROTEINS IDENTIFIED FROM BRAIN TISSUES
WO1999006439A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN ENDODERM
WO1999006553A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN VARIOUS TISSUES
WO1999031236A3 (en) EXTENDED cDNAs FOR SECRETED PROTEINS
WO1999025825A3 (en) EXTENDED cDNAs FOR SECRETED PROTEINS
WO1999040189A3 (en) Cdnas encoding secreted proteins
WO1999054461A3 (en) Human nucleic acid sequences of endometrium tumour tissue
CA2200371A1 (en) Human npik gene
CA2253238A1 (en) Novel agouti-related gene
WO2001000806A3 (en) Dna's encoding proteins with signal peptides
WO2000037491A3 (en) Dnas encoding proteins with signal sequences
WO1999054460A3 (en) Human nucleic acid sequences of normal bladder tissue
WO1999054353A3 (en) Human nucleic acid sequences of normal uterus tissue
WO1999054447A3 (en) Human nucleic acid sequences of bladder tumour tissue
WO1999054448A3 (en) Human nucleic acid sequences, increased expression thereof in uterus myoma tissue
WO1999054446A3 (en) Human nucleic acid sequences which are overexpressed in normal pancreas tissue
EP1903111A3 (en) Extended cDNAs for secreted proteins
EP1557425A3 (en) 123 human secreted proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: B1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2296287

Country of ref document: CA

Ref country code: CA

Ref document number: 2296287

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 85551/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998936590

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998936590

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 1998936590

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998936590

Country of ref document: EP